In this multicenter , randomized , open-label , active-comparator , phase @ trial , @ patients were randomized @:@ to receive edoxaban @mg once daily ( n = @ ) or enoxaparin sodium ( enoxaparin ) @IU ( equivalent to @mg ) twice daily ( n = @ ) for @ to @days .